1 Kakogawa East City Hospital, Japan BACKGROUND MCG (Multifunction CardioGram) is new technology developed by Premier Heart in USA. Analyze cardiovascular function (mainly ischemia) by frequency digitalized ECG data which is obtained approximately 7 minutes of 2 leads (II and V5) of resting ECG. (Total testing time is 20-30 minutes.) Data is transmitted through the internet to the data center in the USA and analyzed automatically. "Analyze" is categorized as a medical device in the USA (Class I). CPT code is obtained (j applicable health insurance). In Japan, it is not categorized as medical device. (Not applicable pharmaceutical jurisprudence and insurance).
MCG analyzes patient's information, comparing to a database of over 40.000 patients' electrocardiograms at rest. A numeric score is assigned on this analysis representing the likelihood and severity of CAD, using a score from 0 to 20, with a score of 4.0 or higher indicating CO (coronary obstruction).
The study group consists of 95 patients, (mean age at 67.4AE9.3, Male; 69 patients and Female; 26 patients), who are planning to or underwent CAG or MDCT, SPECT.
For these patients, using MCG testing, with the data transferred over the internet to Premier Heart in New York for analysis, sensitivity and specificity for patients of stenosis was ! 75%.
METHODS MCG analyzes patient's information, comparing to a database of over 40.000 patients' electrocardiograms at rest. Obtain resting ECG data of the patient with stable condition. Total time will be approximately 20-30 minutes including resting time before testing. Time for analyze will be a few minutes after transmitting data. A numeric score is assigned on this analysis representing the likelihood and severity of CAD, using a score from 0 to 20, with a score of 4.0 or higher indicating CO (coronary obstruction). We performed fully informed consent. After that, we performed MCG test, 117cases. The study group consists of 95 patients, (mean age at 67.4AE9.3, Male; 69 patients and Female; 26 patients), who are planning to or underwent CAG or MDCT, SPECT. For these patients, using MCG testing, with the data transferred over the internet to Premier Heart in New York for analysis, sensitivity and specificity for patients of stenosis was ! 75%. 22cases were excluded. The reasons were MCG ECG quality level all poor, test after PCI, CAG or SPECT negative.
RESULTS
Baseline characteristics were no different between 2groups, MCG scoreS4.0 and ＜4.0. At the cut-off of 4.0 indicating CO, accuracy is 62.1%, sensitivity is 65.3%, specificity is 52.2%, PPV is 81.0%, and NPV is 32.4%.
However revisiting the cut-off to 3.0 to reflect indication of CO, the data reflects accuracy is 70.5%, sensitivity is 83.3%, specificity is 30.4%, PPV is 78.9%, and NPV is 36.8%. Despite cut-off being 4.0,the outcome showed increased reliability after including the MCG session analysis, with accuracy at 78.9%,sensitivity at 95.8%,specificity at 26.1%,PPV at 80.2% and NPV at 66.7%.
The cases tested by all of CAG/SPECT/MCG: n¼86 1. By setting only 75% S CAG stenosis was positive; compare the ROC of SPECT and MCG with CAG. Positive: 71 cases Negative: 15 cases (CAG result only, excluding OMI, etc.) 2. Applying Cutoff score 4þ 4 secondary and tertiary index.
1. The 75% S CAG stenosis was found when SPECT was positive and False Positive case for SPECT was 0. However, SPECT can't detect False Negative 19patient (27%) and the number of True Positive cases was lower than the MCG.(67vs 52) 2. The MCG had more False Positive than True Negative. However, within the False Positive patient heart abnormality such as OMI, VSAP, wall motion abnormality or heart failure patients were included and these abnormality might have contributed to FP. 3. In conclusion, the MCG showed a high accuracy for screening coronary artery disease.
CONCLUSION Subjects included in the trial were ambulatory patients who presented to their physicians for evaluation with either Coronary Angiography or SPECT-MPI.
This might influence on the high accuracy .sensitivity and PPV of this study.
Considering the use in the health checkup center, further study targeting for low risk population might be important to find out the relation between CAD risk factors and the MCG score within low risk population. Optima medical therapy is important method for treating coronary artery disease with a exception of acute coronary syndromes or confirmed is chemic patient. Also it is a very important treatment as a primary and secondary prevention for CAD. However, there is an issue with optimal medical therapy that is difficult to get consensus especially from the symptomatic patient.
Through this study it was suggested that the MCG test, which is an easy noninvasive test with high accuracy for CAD risk, might motivate patient toward optimal medical therapy from the primary prevention stage. Through this study it was suggested that the MCG test is very useful for screening CAD risk of S 75% stenosis. The MCG test is noninvasive test and can be applied regardless patient characteristic such as age, kidney function and ADL.
TCTAP A-087 Acute Thrombosis of AV Fistula in Chronic Kidney Disease Patients -Effect of Intra-Arterial Thrombolysis: Our Experience Ramesh Gadepalli 1 1 Nizam's Institute of Medical Sciences, India BACKGROUND Hemodialysis fistulas are surgically created communications between native artery and vein in an extremity. Many patients who are not candidates for renal transplantation are dependent on hemodialysis for their lifetime resulting in long-term need for use of dialysis access. 25% of hospital admissions in the dialysis population have been attributed to vascular access problems, including fistula malfunction and thrombosis. Historically, native fistula malfunction and thrombosis were treated by using surgical thrombectomy and revision, resulting in the eventual exhaustion of the veins and the need to create a new access. We have treated the acute av fistula thrombosis with intra-arterial thrombolysis and report the data.
METHODS
The study period was 1year from Jan 2013-2014. A total of 48 ESRD patients on maintenance hemodialysis were included. Thrombosis of AVF was documented by Doppler and confirmed by Fistulogram. Intraarterial thrombolysis was done through femoral arterial access with a pigtail catheter inserted in to the brachial artery for brachiocephalic AVF and into radial artery just after bifurcation of the brachial artery for radio-cephalic AVF. Inj. Streptokinase was given as a Bolus of 2.5lakh units followed by a maintenance dose of 1 lakh units/hour for 24 to 48hours. Check fistulogram was done after 24hrs. Procedural success reaffirmed by performing dialysis in successful patients.
RESULTS
The Mean age of patients was 44AE15.73years (Range:18-62years). Angiography was suggestive of thrombosis at juxtTCTAP A-anastomotic (n¼12), arterial (n¼12) and venous (n¼24) site. Procedural success with at least one dialysis session was noted in 50% of the patients (24 of 48 patients). Two patients required re-intervention after 6 months. One ADPKD patient had cyst hemorrhage requiring blood transfusion who subsequently improved. Four minor complications like hematemesis (n¼2), and bleeding from the site of catheterization (N¼2) were noted. 
